Cite
APA Citation
Sengupta, N. K., Azizov, A., Halder, S., Xenodemetropoulos, T., Armstrong, D., Tse, F., Marshall, J. K., & Narula, N. (2020). higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian journal of gastroenterology, 55, 800–805. http://access.bl.uk/ark:/81055/vdc_100105873313.0x000058